Your browser doesn't support javascript.
loading
Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views.
Dagan, Noa; Cohen-Stavi, Chandra J; Avgil Tsadok, Meytal; Leibowitz, Morton; Hoshen, Moshe; Karpati, Tomas; Akriv, Amichay; Gofer, Ilan; Gilutz, Harel; Podjarny, Eduardo; Bachmat, Eitan; Balicer, Ran D.
Afiliação
  • Dagan N; 1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Cohen-Stavi CJ; 2Computer Science Department, Ben Gurion University of the Negev, Be'er Sheba, Israel.
  • Avgil Tsadok M; 3Public Health Department, Ben Gurion University of the Negev, Be'er Sheba, Israel.
  • Leibowitz M; 1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Hoshen M; 1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Karpati T; 1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Akriv A; 1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Gofer I; 1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Gilutz H; 1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Podjarny E; 1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Bachmat E; 1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Balicer RD; 4ADAM Institute of High Blood Pressure, Clalit Health Services, Hertzlia, Israel.
NPJ Digit Med ; 2: 81, 2019.
Article em En | MEDLINE | ID: mdl-31453376
ABSTRACT
Currently, clinicians rely mostly on population-level treatment effects from RCTs, usually considering the treatment's benefits. This study proposes a process, focused on practical usability, for translating RCT data into personalized treatment recommendations that weighs benefits against harms and integrates subjective perceptions of relative severity. Intensive blood pressure treatment (IBPT) was selected as the test case to demonstrate the suggested process, which was divided into three phases (1) Prediction models were developed using the Systolic Blood-Pressure Intervention Trial (SPRINT) data for benefits and adverse events of IBPT. The models were externally validated using retrospective Clalit Health Services (CHS) data; (2) Predicted risk reductions and increases from these models were used to create a yes/no IBPT recommendation by calculating a severity-weighted benefit-to-harm ratio; (3) Analysis outputs were summarized in a decision support tool. Based on the individual benefit-to-harm ratios, 62 and 84% of the SPRINT and CHS populations, respectively, would theoretically be recommended IBPT. The original SPRINT trial results of significant decrease in cardiovascular outcomes following IBPT persisted only in the group that received a "yes-treatment" recommendation by the suggested process, while the rate of serious adverse events was slightly higher in the "no-treatment" recommendation group. This process can be used to translate RCT data into individualized recommendations by identifying patients for whom the treatment's benefits outweigh the harms, while considering subjective views of perceived severity of the different outcomes. The proposed approach emphasizes clinical practicality by mimicking physicians' clinical decision-making process and integrating all recommendation outputs into a usable decision support tool.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: NPJ Digit Med Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: NPJ Digit Med Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Israel